J&J preps case for quick FDA approval of new TB drug
from Fierce Biotech
Johnson & Johnson has set out to navigate its way through an important stage of its campaign to gain an accelerated approval for a new therapy for drug-resistant tuberculosis. A panel of outside FDA experts will give J&J's bedaquiline team a thorough examination to see whether the company warrants a preliminary approval based on Phase II data. And recently, the agency released its carefully neutral view of the data on safety and efficacy.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063